ES2094231T3 - Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion. - Google Patents

Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.

Info

Publication number
ES2094231T3
ES2094231T3 ES91914023T ES91914023T ES2094231T3 ES 2094231 T3 ES2094231 T3 ES 2094231T3 ES 91914023 T ES91914023 T ES 91914023T ES 91914023 T ES91914023 T ES 91914023T ES 2094231 T3 ES2094231 T3 ES 2094231T3
Authority
ES
Spain
Prior art keywords
cells
lysis
conjugate
targeted
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91914023T
Other languages
English (en)
Inventor
Terje Kalland
Gunnar Hedlund
Mikael Dohlsten
Peter Lando
Eva Akerblom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002484A external-priority patent/SE9002484L/xx
Priority claimed from SE9002479A external-priority patent/SE9002479D0/xx
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2094231T3 publication Critical patent/ES2094231T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN CONJUGADO SOLUBLE DE ANTICUERPOS QUE COMPRENDE UN ANTICUERPO UNIDO A UNA ESTRUCTURA QUE ES RECONOCIBLE POR LAS CELULAS T Y TIENE LA CAPACIDAD DE DIRIGIR LAS CELULAS T HACIA LA LISIS DE LA CELULA OBJETIVADA, QUE ES RECONOCIDA POR EL ANTICUERPO. EL CONJUGADO SE CARACTERIZA PORQUE SU ESTRUCTURA ES UN SUPERANTIGENO. UN MODO IMPORTANTE ES UN METODO PARA LA LISIS DE CELULAS OBJETIVADAS, EN EL QUE LAS CELULAS OBJETIVADAS SE PONEN EN CONTACTO CON UNA CANTIDAD EFECTIVA PARA LA LISIS DE LAS CELULAS DEL CONJUGADO. EL METODO DE LISIS ES PARTE DE UN REGIMEN DE TRATAMIENTO POTENTE PARA EL CANCER, LA AUTOINMUNIDAD, LAS INFECCIONES PARASITICAS Y LAS INFECCIONES FUNGALES, VIRALES Y BACTERIANAS. LAS ESPECIFICACIONES TAMBIEN DESCRIBEN MODOS TALES COMO LA SINTESIS DEL CONJUGADO Y COMPOSICIONES FARMACEUTICAS Y SU MANUFACTURA.
ES91914023T 1990-07-20 1991-07-16 Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion. Expired - Lifetime ES2094231T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002484A SE9002484L (sv) 1990-07-20 1990-07-20 Nya substituerade polyetrar
SE9002479A SE9002479D0 (sv) 1990-07-20 1990-07-20 Antibody conjugates

Publications (1)

Publication Number Publication Date
ES2094231T3 true ES2094231T3 (es) 1997-01-16

Family

ID=26660818

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91914023T Expired - Lifetime ES2094231T3 (es) 1990-07-20 1991-07-16 Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.

Country Status (16)

Country Link
EP (1) EP0610179B1 (es)
JP (1) JP3334130B2 (es)
KR (1) KR100189024B1 (es)
AT (1) ATE144145T1 (es)
AU (1) AU656906B2 (es)
CA (1) CA2087164C (es)
DE (1) DE69122777T2 (es)
DK (1) DK0610179T3 (es)
ES (1) ES2094231T3 (es)
GR (1) GR3022202T3 (es)
HK (1) HK1007955A1 (es)
HU (1) HU218603B (es)
LV (1) LV10201B (es)
NO (1) NO312816B1 (es)
RU (1) RU2125889C1 (es)
WO (1) WO1992001470A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
GB9114399D0 (en) * 1991-07-03 1991-08-21 Ici Plc Conjugates
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
EP0659438A1 (en) * 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
GB9326574D0 (en) * 1993-12-31 1994-03-02 King S College London Dry power inhalers
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
JP3871713B2 (ja) 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2516794B1 (fr) * 1981-11-20 1985-10-25 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
EP0334300A1 (en) * 1988-03-21 1989-09-27 Neorx Corporation The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体

Also Published As

Publication number Publication date
JP3334130B2 (ja) 2002-10-15
EP0610179A1 (en) 1994-08-17
GR3022202T3 (en) 1997-03-31
JPH05508856A (ja) 1993-12-09
KR100189024B1 (ko) 1999-06-01
NO312816B1 (no) 2002-07-08
WO1992001470A1 (en) 1992-02-06
DE69122777D1 (de) 1996-11-21
LV10201B (en) 1995-08-20
CA2087164C (en) 2002-11-26
HU9300148D0 (en) 1993-04-28
LV10201A (lv) 1994-10-20
RU2125889C1 (ru) 1999-02-10
NO930174D0 (no) 1993-01-19
AU8294191A (en) 1992-02-18
ATE144145T1 (de) 1996-11-15
CA2087164A1 (en) 1992-01-21
HU218603B (hu) 2000-10-28
AU656906B2 (en) 1995-02-23
HK1007955A1 (en) 1999-04-30
DK0610179T3 (da) 1997-03-24
NO930174L (no) 1993-01-19
DE69122777T2 (de) 1997-04-10
HUT67502A (en) 1995-04-28
EP0610179B1 (en) 1996-10-16

Similar Documents

Publication Publication Date Title
ES2733238T1 (es) Tratamiento de linfoma no Hodkings de grados intermedio y alto con anticuerpo anti CD20
ATE144145T1 (de) Zielgerichtete spezifische antikörper- superantigen konjugate und ihre präparation
CL2024002235A1 (es) Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso.
EP3941945A4 (en) ANTITROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP2) ANTIBODIES AND ANTIBODY-DRUG CONJUGATES THEREOF
DK0693132T3 (da) Rapamycinassay
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
DE60026691D1 (de) Staphylococcus-antigene und impstoff
ES2115596T3 (es) Recombinados inmunoconjugados para terapias que comprenden interleucina-2.
CY1113298T1 (el) Ανασυνδυασμενα αντισωματα υψηλης ισχυος και μεθοδος παραγωγης αυτων
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
EP0044167A3 (en) Antibody targeted cytotoxic agent
DK0532525T3 (da) Nye protein-polykationkonjugater
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
RU93004918A (ru) Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции
ES2099075T3 (es) Conjugados de antraciclina con un nuevo engarce y procedimientos para su produccion.
DK0577648T3 (da) Nye protein-polykation-konjugater
ATE41414T1 (de) Acetaminophenanaloge, 1-antigene und -antikoerper.
JOP20250172A1 (ar) مُقترنات الأدوية والأجسام المضادة لـ cd70
MX2024001301A (es) Anticuerpos y conjugados de anticuerpo especificos para nectina 4 y metodos de uso de los mismos.
WO2024211236A3 (en) Antibody-drug conjugates and uses thereof
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
ES2065525T3 (es) Mejoras relacionadas con el radiomarcado de las proteinas.
RU98104739A (ru) Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
CA2141025A1 (en) Anti-mucus glycoprotein monoclonal antibody

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 610179

Country of ref document: ES